Demineralized bone matrix combined with cytotoxic T‐lymphocyte‐associated protein 4 promotes osteogenic differentiation of human bone marrow mesenchymal stem cells and suppresses the activation of T lymphocytes in vitro
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Tissue Engineering and Regenerative Medicine"
DOI: 10.1002/term.3281
Abstract: Cytotoxic T‐lymphocyte‐associated protein 4 (CTLA4) can promote osteogenic differentiation of human bone marrow mesenchymal stem cells (hBMMSCs), and CTLA4‐modified bone marrow mesenchymal stem cells possess immunoregulatory effects. In the present study, we aimed to construct… read more here.
Keywords: bone; dbm ctla4; osteogenic differentiation; protein ... See more keywords
Inhibition of SRC family kinases facilitates anti-CTLA4 immunotherapy in head and neck squamous cell carcinoma
Sign Up to like & getrecommendations! Published in 2018 at "Cellular and Molecular Life Sciences"
DOI: 10.1007/s00018-018-2863-3
Abstract: The immune system plays a critical role in the establishment, development, and progression of head and neck squamous cell carcinoma (HNSCC). As treatment with single-immune checkpoint agent results in a lower response rate in patients,… read more here.
Keywords: ctla4 immunotherapy; anti ctla4; ctla4; cell ... See more keywords
Development of a fully canine anti-canine CTLA4 monoclonal antibody for comparative translational research in dogs with spontaneous tumors
Sign Up to like & getrecommendations! Published in 2021 at "mAbs"
DOI: 10.1080/19420862.2021.2004638
Abstract: ABSTRACT The immune checkpoint inhibitor (ICI) ipilimumab has revolutionized the treatment of patients with different cancer histologies, including melanoma, renal cell carcinoma, and non-small cell lung carcinoma. However, only a subset of patients shows dramatic… read more here.
Keywords: canine ctla4; spontaneous tumors; canine anti; fully canine ... See more keywords
EOMES/TBET and soluble CTLA4/full length CTLA4 expression ratios impact on the therapeutic response in patients with classical Hodgkin lymphoma
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Haematology"
DOI: 10.1111/bjh.15253
Abstract: Lori E. Heath Jack Knorr E. Tsiri Agbenyega Raffaella Colombatti Carlton Dampier Hoda Hassab Deepa Manwani Nancy Robitaille Patricia B. Brown Joseph A. Jakubowski Suqin Yao Carolyn Hoppe Medical University of South Carolina, Charleston, SC,… read more here.
Keywords: eomes tbet; medicine; soluble ctla4; ctla4 ... See more keywords
The role of CD28 in adult T‐cell leukaemia/lymphoma
Sign Up to like & getrecommendations! Published in 2020 at "British Journal of Haematology"
DOI: 10.1111/bjh.17214
Abstract: T-cell-specific surface glycoprotein CD28 belongs to the subfamily of costimulatory molecules characterized by an extracellular immunoglobulin variable-like domain. Other members of the subfamily include inducible T-cell costimulator (ICOS), cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), programmed cell… read more here.
Keywords: icos; cell leukaemia; cd28; ctla4 ... See more keywords
Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy
Sign Up to like & getrecommendations! Published in 2017 at "Science Advances"
DOI: 10.1126/sciadv.1602133
Abstract: Cooperative therapeutic effect of anti-CTLA4 and anti-sMIC antibodies. Antibody therapy targeting cytotoxic T lymphocyte–associated antigen 4 (CTLA4) elicited survival benefits in cancer patients; however, the overall response rate is limited. In addition, anti-CTLA4 antibody therapy… read more here.
Keywords: antibody therapy; anti ctla4; antibody; ctla4 antibody ... See more keywords
FRI0418 In vitro effects of ctla4-ig treatment on cultured fibrocytes from systemic sclerosis patients
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.5173
Abstract: Background Circulating fibrocytes (CFs) are progenitor cells derived from bone marrow, expressing markers of both hematopoietic cells (CD45, MHC class II) and stromal cells (collagen I and III), together with the chemokine receptors, which regulate… read more here.
Keywords: none declared; ssc; cfs; ctla4 ... See more keywords
Antitumor efficacy of combined CTLA4/PD-1 blockade without intestinal inflammation is achieved by elimination of FcγR interactions
Sign Up to like & getrecommendations! Published in 2020 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2020-001584
Abstract: Background Programmed cell death protein 1 (PD-1) and CTLA4 combination blockade enhances clinical efficacy in melanoma compared with targeting either checkpoint alone; however, clinical response improvement is coupled with increased risk of developing immune-related adverse… read more here.
Keywords: combination; anti ctla4; blockade; inflammation ... See more keywords
Abstract 2734: Novel CTLA4 antibodies demonstrate potent antitumor activity in a humanized mouse model
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-2734
Abstract: CTLA4 (cytotoxic T-lymphocyte-associated protein 4), is a member of the immunoglobulin superfamily. It is expressed in T cells upon activation and transmits an inhibitor signal to T cells. Also, it is constitutively expressed in regulatory… read more here.
Keywords: ctla4; ctla4 antibodies; novel ctla4; cancer ... See more keywords
Abstract 2536: Intracellular Ctla4 overexpression promotes melanoma progression and metastasis
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-2536
Abstract: Cytotoxic T Lymphocyte Antigen 4 (CTLA4) expressed on the surface of T cells is an important immunotherapeutic target in many cancers, including melanoma. However, we previously found highly upregulated expression of CTLA4 in BRAF/NRAS-mutant human… read more here.
Keywords: progression metastasis; melanoma progression; ctla4; melanoma ... See more keywords
CTLA4-Ig in combination with FTY720 promotes allograft survival in sensitized recipients.
Sign Up to like & getrecommendations! Published in 2017 at "JCI insight"
DOI: 10.1172/jci.insight.92033
Abstract: Despite recent evidence of improved graft outcomes and safety, the high incidence of early acute cellular rejection with belatacept, a high-affinity CTLA4-Ig, has limited its use in clinical transplantation. Here we define how the incomplete… read more here.
Keywords: allograft survival; fty720; graft; ctla4 ... See more keywords